resistant depression

Depression and Chronic Diseases: It Is Time for a Synergistic Mental Health and Primary Care Approach.

Depression and chronic diseases: it is time for a synergistic mental health and primary care approach.

Prim Care Companion CNS Disord. 2013; 15(2):
Voinov B, Richie WD, Bailey RK

Objective: To identify the growing significance of depression as a… Continue reading

Advances in Brain Stimulation for Depression.

Advances in brain stimulation for depression.

Ann Clin Psychiatry. 2013 Aug; 25(3): 217-24
Wani A, Trevino K, Marnell P, Husain MM

Major depressive disorder is a common and debilitating psychiatric disorder that negatively impacts a large portion of the… Continue reading

Anandamide, Cannabinoid Type 1 Receptor, and NMDA Receptor Activation Mediate Non-Hebbian Presynaptically Expressed Long-Term Depression at the First Central Synapse for Visceral Afferent Fibers.

Anandamide, Cannabinoid Type 1 Receptor, and NMDA Receptor Activation Mediate Non-Hebbian Presynaptically Expressed Long-Term Depression at the First Central Synapse for Visceral Afferent Fibers.

J Neurosci. 2013 Jul 31; 33(31): 12627-37
Khlaifia A, Farah H, Gackiere F, Tell F… Continue reading

Opportunities for Reversible Inhibitors of Monoamine Oxidase-a (RIMAs) in the Treatment of Depression.

Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression.

CNS Spectr. 2012 Sep; 17(3): 107-20
Lum CT, Stahl SM

Treatment-resistant depression (TRD) may be implicated in 33–57% of depression cases. The currently available effective treatments… Continue reading

Repetitive Transcranial Magnetic Stimulation to Maintain Treatment Response to Electroconvulsive Therapy in Depression: A Case Series.

Repetitive transcranial magnetic stimulation to maintain treatment response to electroconvulsive therapy in depression: a case series.

Front Psychiatry. 2013; 4: 73
Noda Y, Daskalakis ZJ, Ramos C, Blumberger DM

Electroconvulsive therapy (ECT) is the most effective treatment for a… Continue reading

Neurocrine Biosciences, Inc. (NBIX): Why We Think Neurocrine's Phase IIb Trial

Neurocrine Biosciences, Inc. (NBIX): Why We Think Neurocrine's Phase IIb Trial
Tardive dyskinesia is among the most severe side effects caused by dopamine blockers (neuroleptics), which are widely used in the treatment of schizophrenia, bipolar disorder, treatment-resistant depression, and… Continue reading

Five Questions to Ask Your Doctor About Depression

Five Questions to ask Your Doctor about Depression
Nearly half of people with MDD are not receiving any treatment and the consequences can be devastating.Some believe they should just “snap out of it” on their own. Others do not discuss… Continue reading

A Choice-Based Screening Method for Compulsive Drug Users in Rats.

A Choice-Based Screening Method for Compulsive Drug Users in Rats.

Curr Protoc Neurosci. 2013 Jul; Chapter 9: Unit9.44
Lenoir M, Augier E, Vouillac C, Ahmed SH

We describe a protocol for screening compulsive drug users among cocaine self-administering rats,… Continue reading

Perception of Chronic Respiratory Impairment in Patients’ Drawings.

Perception of chronic respiratory impairment in patients’ drawings.

J Rehabil Med. 2013 Jun 24;
Luthy C, Cedraschi C, Pasquina P, Uldry C, Junod-Perron N, Janssens JP

Objective: To explore the perception of dyspnoea in patients with severe chronic obstructive… Continue reading

Clinical Site Services – Sheppard Pratt – Treatment-Resistant Depression


 

Clinical Site Services – Sheppard Pratt – Treatment-resistant Depression – Clinical Site Services – Sheppard Pratt – Treatment-resistant Depression.

 

Jamp;Js Promising Pharma Pipeline
Key candidates in the Neuroscience segment include fulranumab (osteoarthritic pain), esketamine (phase II for treatment-resistant… Continue reading